Radiation dose from radiopharmaceuticals contaminated with molybdenum-99.
Sixteen patients undergoing routine nuclear imaging procedures were injected with 99mTc-labeled radiopharmaceuticals containing 99Mo which exceeded the recommended limit of 1 microCi of 99mMo per mCi of 99mTc. The kinetics of the resulting 99Mo distribution in 14 of these patients were studied over a period of several weeks. The mean biologic half-life [T 1/2b] ranged from about 19.3 days to 11.2 days depending on the model used. Similarly, the mean radiation dose to the liver ranged from approximately 0.02 rad/microCi of 99Mo to 0.05 microCi of 99Mo.
Shearer
D R
DR
Rhode Island Hospital, Providence 02902.
Pezzullo
J C
JC
Moore
M M
MM
Coleman
P
P
Frater
S I
SI
D006801:Humans; D008982:Molybdenum; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011829:Radiation Dosage; D011868:Radioisotopes; D011876:Radionuclide Generators; D013670:Sodium Pertechnetate Tc 99m; D013667:Technetium; D013668:Technetium Tc 99m Aggregated Albumin; D013669:Technetium Tc 99m Medronate; D016284:Technetium Tc 99m Pentetate; D013671:Technetium Tc 99m Sulfur Colloid
D009942:Organometallic Compounds; D011868:Radioisotopes; D013668:Technetium Tc 99m Aggregated Albumin; D013671:Technetium Tc 99m Sulfur Colloid; D013667:Technetium; D004369:Pentetic Acid; D008982:Molybdenum; D013670:Sodium Pertechnetate Tc 99m; D016284:Technetium Tc 99m Pentetate; D013669:Technetium Tc 99m Medronate